Get the Stockscreener App
2.85
3.06%
-0.09
Protalix BioTherapeutics Inc. stock is traded at $2.85, with a volume of 795.31K.
It is down -3.06% in the last 24 hours and up +12.65% over the past month.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
See More
Previous Close:
$2.94
Open:
$2.99
24h Volume:
795.31K
Relative Volume:
1.13
Market Cap:
$198.98M
Revenue:
$63.63M
Net Income/Loss:
$10.62M
P/E Ratio:
57.00
EPS:
0.05
Net Cash Flow:
$-8.64M
1W Performance:
+9.20%
1M Performance:
+12.65%
6M Performance:
+163.89%
1Y Performance:
+141.53%
1-Day Range:
$2.84
$3.04
1-Week Range:
$2.50
$3.04
52-Week Range:
$0.8214
$3.04
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Name
Protalix BioTherapeutics Inc.
Sector
Industry
Phone
972 4 988 9488
Address
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.85 | 198.98M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-17-17 | Reiterated | Rodman & Renshaw | Buy |
| Apr-04-16 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-15 | Upgrade | Jefferies | Hold → Buy |
| Nov-12-14 | Reiterated | R. F. Lafferty | Buy |
| Jan-24-14 | Initiated | R. F. Lafferty | Buy |
| May-02-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-02-12 | Reiterated | Oppenheimer | Outperform |
| Apr-30-12 | Downgrade | Auriga | Buy → Hold |
| Oct-13-11 | Initiated | Morgan Joseph | Hold |
| Mar-17-11 | Downgrade | WBB Securities | Strong Buy → Buy |
| Nov-09-10 | Reiterated | Oppenheimer | Outperform |
| Oct-14-10 | Reiterated | UBS | Buy |
| Dec-02-09 | Reiterated | Hapoalim | Outperform |
| Sep-22-09 | Initiated | Canaccord Adams | Buy |
| Sep-02-09 | Initiated | Hapoalim | Outperform |
| Dec-01-08 | Reiterated | Oppenheimer | Outperform |
| Mar-11-08 | Initiated | UBS | Buy |
| Nov-20-07 | Initiated | CIBC Wrld Mkts | Sector Outperform |
View All
Protalix BioTherapeutics Inc. Stock (PLX) Latest News
PLX’s earnings estimates: Are they on track to meet expectations? - uspostnews.com
Protalix BioTherapeutics Inc Inc. (PLX) Price Performance: A Technical Analysis Perspective - investchronicle.com
Protalix CFO Eyal Rubin to resign in six months By Investing.com - Investing.com Nigeria
Protalix BioTherapeutics' CFO Rubin to Leave - MarketWatch
Protalix stock soars to 52-week high, hits $2.76 By Investing.com - Investing.com South Africa
Eyal Rubin Resigns As CFO Of Protalix BiotherapeuticsSEC Filing - marketscreener.com
Protalix CFO Eyal Rubin to resign in six months - Investing.com
Protalix stock soars to 52-week high, hits $2.76 - Investing.com
The growth track for Protalix BioTherapeutics Inc (PLX) has changed recently - Sete News
Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline - Seeking Alpha
Fabry Disease Treatment Market Opportunity and Forecast Report 2025-2034 Featuring Amicus Therapeutics, Avrobio, Freeline, Idorsia, ISU Abxis, JCR, Novartis, Pfizer, Protalix, Sanofi, Takeda, Viatris - Yahoo Finance
Protalix BioTherapeutics to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 12, 2020 - BioSpace
Fabry Disease Treatment Market Deep Research 2025-2032 | - openPR.com
Virtu Financial LLC Has $64,000 Stock Holdings in Protalix BioTherapeutics, Inc. (NYSE:PLX) - Defense World
[Latest] Global Fabry Disease Treatment Market Size/Share Worth USD 7.02 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.
Protalix Biotherapeutics is developing innovative treatments for rare diseases with its proprietary ProCellEx plant cell expression system - Proactive financial news
Protalix BioTherapeutics And 2 Other Promising Penny Stocks - simplywall.st
Protalix to present at iAccess Alpha Virtual Investment Conference 2025 - Proactive financial news
Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025 - Financial Times
Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now? - Insider Monkey
Nvidia, Nike, Sarepta Therapeutics, Protalix and more analyst calls of the week - Proactive Investors
Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipelineICYMI - Proactive financial news
FY2025 Earnings Estimate for PLX Issued By Zacks Small Cap - Defense World
Protalix BioTherapeutics (NYSE:PLX) Stock Rating Lowered by StockNews.com - Defense World
Protalix Stock (PLX) Grabbing Attention with Record Revenue Surge - markets.businessinsider.com
Small cap wrap: Fineqia, Candel Therapeutics, Ocean Power Technologies, Protalix Biotherapeutics... - Proactive Investors
Protalix Biotherapeutics gains momentum: analysts see long-term upside - Proactive Investors USA
Protalix BioTherapeutics pipeline eyes gout treatment as financial strength fuels future growth - Proactive financial news
Protalix BioTherapeutics : Chiesi Global Rare Diseases Announces Multiple Presentations on pegunigalsidase alfa and Fabry Disease at the 21st Annual WORLDSymposium™ Research Meeting - Marketscreener.com
Protalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidate - Proactive Investors UK
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2024 Earnings Call Transcript - Insider Monkey
PLX: 2024 Results - Yahoo Finance
Protalix BioTherapeutics Inc (PLX) Q4 2024 Earnings Call Highlights: Record Revenue Growth ... - Yahoo
Protalix BioTherapeutics Inc (PLX) Q4 2024 Earnings Call Highlights: Record Revenue Growth ... By GuruFocus - Investing.com Canada
Protalix BioTherapeutics Reports Record Revenue and Clinical Progress - TipRanks
Earnings call transcript: Protalix Q4 2024 sees 31% revenue growth By Investing.com - Investing.com Canada
Protalix plans Phase 2 for PRX-115 in H2 2025, projects higher royalty revenues by 2030 - MSN
Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond - Benzinga
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Earnings call transcript: Protalix Q4 2024 sees 31% revenue growth - Investing.com
Protalix BioTherapeutics Inc. (DE) (PLX) reports earnings - Quartz
Protalix Q4 Earnings Fall, Stock Up In Pre-market - Nasdaq
Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results - GuruFocus.com
StockNews.com Upgrades Protalix BioTherapeutics (NYSE:PLX) to “Strong-Buy” - Defense World
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference - Kilgore News Herald
Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025 - Quantisnow
Protalix BioTherapeutics to Report FY2024 Earnings on March 17 - Stock Titan
Protalix BioTherapeutics (NYSE:PLX) and INmune Bio (NASDAQ:INMB) Head-To-Head Review - The AM Reporter
Protalix Biotherapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Protalix BioTherapeutics Inc. Stock (PLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):